Last reviewed · How we verify
norepinephrine perfusion
At a glance
| Generic name | norepinephrine perfusion |
|---|---|
| Also known as | vasopressor, catecholamine |
| Sponsor | Central Hospital, Nancy, France |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Laboratory Evaluation of Chronic Autonomic Failure
- Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis (PHASE3)
- Hand Perfusion and Pulse Oximetry Performance
- Different Norepinephrine Doses on Accuracy of Peripheral Perfusion Index in Predicting Tissue Perfusion in Septic Shock Patients (NA)
- Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension
- Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease (PHASE2, PHASE3)
- Weaning of Norepinephrine Guided by the Dynamic Arterial Compliance in Cardiac Surgery Post Operative. (PHASE3)
- Early Transcranial Doppler Goal Directed Therapy After Cardiac Arrest: a Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- norepinephrine perfusion CI brief — competitive landscape report
- norepinephrine perfusion updates RSS · CI watch RSS
- Central Hospital, Nancy, France portfolio CI